The use of monoclonal antibodies against activated human T cells following renal allografting in the baboon.

The use of monoclonal antibodies against activated human T cells following renal allografting in the baboon.

Bibliografske podrobnosti
Main Authors:	Friend, P, Tighe, H, Lim, S, Collier, D, Decurtins, M, Gilliland, L, Thiru, S, Calne, R, Waldmann, H
Format:	Journal article
Jezik:	English
Izdano:	1987

Podobne knjige/članki

Delayed allograft rejection in primates treated with anti-IL-2 receptor monoclonal antibody Campath-6.
od: Tighe, H, et al.
Izdano: (1988)

MONOCLONAL-ANTIBODIES THAT RECOGNIZE ACTIVATED HUMAN-LYMPHOCYTES - EXPERIMENTAL AND CLINICAL-STUDIES
od: Friend, P, et al.
Izdano: (1988)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
od: Friend, P, et al.
Izdano: (1991)

CD4 monoclonal antibodies in the preclinical dog renal allograft model.
od: Watson, C, et al.
Izdano: (1993)

Prophylactic use of an antilymphocyte monoclonal antibody following renal transplantation: a randomized controlled trial.
od: Friend, P, et al.
Izdano: (1987)

Immunosuppression of canine renal allograft recipients by CD4 and CD8 monoclonal antibodies.
od: Watson, C, et al.
Izdano: (1994)

CD4 and CD8 monoclonal antibody therapy in the dog: strategies to induce tolerance to renal allografts.
od: Watson, C, et al.
Izdano: (1995)

CD4 and CD8 monoclonal antibody therapy in canine renal allografts.
od: Watson, C, et al.
Izdano: (1994)

Monoclonal antibody targeting of CD4(+) and CD8(+) cells for prolongation of baboon renal allograft survival.
od: Hazinedaroglu, S, et al.
Izdano: (2005)

Production, selection, and testing of monoclonal antibodies to canine leukocytes in the dog kidney allograft model.
od: Davies, H, et al.
Izdano: (1994)

CD4 and CD8 monoclonal antibody therapy: strategies to prolong renal allograft survival in the dog.
od: Watson, C, et al.
Izdano: (1993)

Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.
od: Friend, P, et al.
Izdano: (1995)

THE USE OF MONOCLONAL ANTILYMPHOCYTE ANTIBODIES IN CLINICAL IMMUNOSUPPRESSION
od: Friend, P, et al.
Izdano: (1985)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
od: Friend, P, et al.
Izdano: (1988)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
od: Hale, G, et al.
Izdano: (1986)

INTERACTION OF MONOCLONAL-ANTIBODIES WITH THE IMMUNE-SYSTEM
od: Clark, M, et al.
Izdano: (1986)

Blocking of cytotoxic T cell function by monoclonal antibodies against the CD45 antigen (T200/leukocyte-common antigen).
od: Tighe, H, et al.
Izdano: (1987)

Islet allografting in the dog model: potential therapies for tolerance induction.
od: Brons, I, et al.
Izdano: (1995)

The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies.
od: Clark, M, et al.
Izdano: (1989)

Synergistic monoclonal antibodies for in vitro immunomodulation of dog islets.
od: Brons, I, et al.
Izdano: (1992)

The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation.
od: Friend, P, et al.
Izdano: (1991)

Immunomodulation of dog islets using a cocktail of monoclonal antibodies.
od: Brons, I, et al.
Izdano: (1992)

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.
od: Calne, R, et al.
Izdano: (1998)

CD4 monoclonal antibody pairs for immunosuppression and tolerance induction.
od: Qin, S, et al.
Izdano: (1987)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
od: Naparstek, E, et al.
Izdano: (1999)

Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.
od: Calne, R, et al.
Izdano: (1999)

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.
od: Lockwood, C, et al.
Izdano: (1993)

HUMANIZED MONOCLONAL-ANTIBODY THERAPY FOR SYSTEMIC VASCULITIS
od: Lockwood, C, et al.
Izdano: (1993)

Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
od: Cobbold, S, et al.
Izdano: (1990)

Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
od: Cobbold, S, et al.
Izdano: (1990)

HUMANIZED MONOCLONAL-ANTIBODY (MAB) THERAPY FOR WEGENERS GRANULOMATOSIS (WG)
od: Lockwood, C, et al.
Izdano: (1995)

MONOCLONAL-ANTIBODIES IN SYSTEMIC VASCULITIS - LONG-TERM BENEFIT FROM SHORT-TERM THERAPY
od: Isaacs, J, et al.
Izdano: (1993)

Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies.
od: Lockwood, C, et al.
Izdano: (1996)

Monoclonal antibodies for immunosuppression.
od: Waldmann, H, et al.
Izdano: (1988)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
od: Waldmann, H, et al.
Izdano: (1985)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
od: Waldmann, H, et al.
Izdano: (1985)

Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis.
od: Kyle, V, et al.
Izdano: (1989)

Human monoclonal antibodies: the residual challenge of antibody immunogenicity.
od: Waldmann, H
Izdano: (2014)

Effect of graft perfusion with two CD45 monoclonal antibodies on incidence of kidney allograft rejection.
od: Brewer, Y, et al.
Izdano: (1989)

Manipulation of T-cell responses with monoclonal antibodies.
od: Waldmann, H
Izdano: (1989)